Protagonist Therapeutics (PTGX) return on equity (ROE)

Return on equity · fiscal 2025
-21.2%

Protagonist Therapeutics (PTGX) earned a return on equity of -21.2% in fiscal 2025 (the year ended December 31, 2025). That is 61.9 percentage points lower than the 40.8% of fiscal 2024. Figures as of 18 Nov 2026, 00:44 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-21.2%
Change on fiscal 2024
−61.9 pts
Highest on record
40.8%fiscal 2024
Lowest on record
-96.5%fiscal 2019
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Protagonist Therapeutics return on equity (ROE), in more detail

Across the 10 fiscal years on record (2016–2025), the highest was 40.8% in fiscal 2024 and the lowest -96.5% in fiscal 2019. The fiscal 2025 figure is higher than in 89% of the 9 earlier fiscal years on record, whose median is -34.6%.

History · 10 fiscal years

Return on equity by fiscal year

Protagonist Therapeutics return on equity (ROE), year by year

Protagonist Therapeutics (PTGX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-21.2% 61.9 pts down
202440.8% 64.2 pts up
2023-23.5% 35.6 pts up
2022-59.1% 17.2 pts down
2021-41.8% 18.2 pts down
2020-23.7% 72.9 pts up
2019-96.5% 61.9 pts down
2018-34.6% 4.0 pts down
2017-30.6% 11.8 pts up
2016-42.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Protagonist Therapeutics and comparable companies
CompanyReturn on equityFiscal year
Praxis Precision Medicines PRAX-34.5%2025
Twist Bioscience TWST-16.4%2025
Protagonist Therapeutics PTGX-21.2%2025
Krystal Biotech KRYS16.8%2025
10x Genomics TXG-5.5%2025
HealthEquity HQY10.2%2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PTGX

Protagonist Therapeutics, figure by figure

Protagonist Therapeutics (PTGX) overview: price, valuation and scorecardAll health care companies by market value

Protagonist Therapeutics return on equity (ROE): questions and answers

What is Protagonist Therapeutics's return on equity?

Protagonist Therapeutics (PTGX) earned a return on equity of -21.2% in fiscal 2025 (the year ended December 31, 2025). That is 61.9 percentage points lower than the 40.8% of fiscal 2024.

Is Protagonist Therapeutics's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 89% of the 9 earlier fiscal years on record, whose median is -34.6%.

What are the highest and lowest return on equity figures on record for Protagonist Therapeutics?

Across the 10 fiscal years on record (2016–2025), the highest was 40.8% in fiscal 2024 and the lowest -96.5% in fiscal 2019.

How is Protagonist Therapeutics's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Protagonist Therapeutics (PTGX) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/PTGX/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.